



## mucopolidosis II alpha/beta

Mucopolidosis II alpha/beta (also known as I-cell disease) is a progressively debilitating disorder that affects many parts of the body. Most affected individuals do not survive past early childhood.

At birth, children with mucopolidosis II alpha/beta are small and have weak muscle tone (hypotonia) and a weak cry. Affected individuals grow slowly after birth and usually stop growing during the second year of life. Development is delayed, particularly the development of speech and motor skills such as sitting and standing.

Children with mucopolidosis II alpha/beta typically have several bone abnormalities, many of which are present at birth. Affected individuals may have an abnormally rounded upper back (kyphosis), feet that are abnormally rotated (clubfeet), dislocated hips, unusually shaped long bones, and short hands and fingers. People with this condition also have joint deformities (contractures) that significantly affect mobility. Most children with mucopolidosis II alpha/beta do not develop the ability to walk independently. Affected individuals have dysostosis multiplex, which refers to multiple skeletal abnormalities seen on x-ray.

Other features of mucopolidosis II alpha/beta include a soft out-pouching around the belly-button (umbilical hernia) or lower abdomen (inguinal hernia), heart valve abnormalities, distinctive-looking facial features that are described as "coarse," and overgrowth of the gums (gingival hypertrophy). Vocal cords can stiffen, resulting in a hoarse voice. The airway is narrow, which can contribute to prolonged or recurrent respiratory infections. Affected individuals may also have recurrent ear infections, which can lead to hearing loss.

### Frequency

Mucopolidosis II alpha/beta is a rare disorder, although its exact prevalence is unknown. It is estimated to occur in about 1 in 100,000 to 400,000 individuals worldwide.

### Genetic Changes

Mutations in the *GNPTAB* gene cause mucopolidosis II alpha/beta. This gene provides instructions for making part of an enzyme called GlcNAc-1-phosphotransferase. This enzyme helps prepare certain newly made enzymes for transport to lysosomes. Lysosomes are compartments within the cell that use digestive enzymes to break down large molecules into smaller ones that can be reused by cells. GlcNAc-1-phosphotransferase is involved in the process of attaching a molecule called mannose-6-phosphate (M6P) to specific digestive enzymes. Just as luggage is tagged at the airport to direct it to the correct destination, enzymes are often "tagged" after

they are made so they get to where they are needed in the cell. M6P acts as a tag that indicates a digestive enzyme should be transported to the lysosome.

Mutations in the *GNPTAB* gene that cause mucopolipidosis II alpha/beta prevent the production of any functional GlcNAc-1-phosphotransferase. Without this enzyme, digestive enzymes cannot be tagged with M6P and transported to lysosomes. Instead, they end up outside the cell and have increased digestive activity. The lack of digestive enzymes within lysosomes causes large molecules to accumulate there. Conditions that cause molecules to build up inside lysosomes, including mucopolipidosis II alpha/beta, are called lysosomal storage disorders. The signs and symptoms of mucopolipidosis II alpha/beta are most likely caused by the lack of digestive enzymes within lysosomes and the effects these enzymes have outside the cell.

Mutations in the *GNPTAB* gene can also cause a similar but milder disorder called mucopolipidosis III alpha/beta. Instead of preventing the production of any enzyme, these mutations reduce the activity of GlcNAc-1-phosphotransferase. Mucopolipidosis III alpha/beta and mucopolipidosis II alpha/beta represent two ends of a spectrum of disease severity.

## **Inheritance Pattern**

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

## **Other Names for This Condition**

- I-cell disease
- inclusion cell disease
- MLII
- mucopolipidosis II
- mucopolipidosis type II

## **Diagnosis & Management**

### Genetic Testing

- Genetic Testing Registry: I cell disease  
<https://www.ncbi.nlm.nih.gov/gtr/conditions/C267337/>

### Other Diagnosis and Management Resources

- GeneReview: Mucopolidosis II  
<https://www.ncbi.nlm.nih.gov/books/NBK1828>
- MedlinePlus Encyclopedia: Clubfoot  
<https://medlineplus.gov/ency/article/001228.htm>
- MedlinePlus Encyclopedia: Contracture deformity  
<https://medlineplus.gov/ency/article/003185.htm>
- MedlinePlus Encyclopedia: Kyphosis  
<https://medlineplus.gov/ency/article/001240.htm>

### General Information from MedlinePlus

- Diagnostic Tests  
<https://medlineplus.gov/diagnostictests.html>
- Drug Therapy  
<https://medlineplus.gov/drugtherapy.html>
- Genetic Counseling  
<https://medlineplus.gov/geneticcounseling.html>
- Palliative Care  
<https://medlineplus.gov/palliativecare.html>
- Surgery and Rehabilitation  
<https://medlineplus.gov/surgeryandrehabilitation.html>

## **Additional Information & Resources**

### MedlinePlus

- Encyclopedia: Clubfoot  
<https://medlineplus.gov/ency/article/001228.htm>
- Encyclopedia: Contracture deformity  
<https://medlineplus.gov/ency/article/003185.htm>
- Encyclopedia: Kyphosis  
<https://medlineplus.gov/ency/article/001240.htm>
- Health Topic: Metabolic Disorders  
<https://medlineplus.gov/metabolicdisorders.html>

### Genetic and Rare Diseases Information Center

- I cell disease  
<https://rarediseases.info.nih.gov/diseases/6749/i-cell-disease>

### Additional NIH Resources

- National Institute of Neurological Disorders and Stroke: Mucopolidoses Fact Sheet  
<https://www.ninds.nih.gov/Disorders/All-Disorders/Mucopolidoses-Information-Page>

### Educational Resources

- Disease InfoSearch: Mucopolidosis II  
<http://www.diseaseinfosearch.org/Mucopolidosis+II/3706>
- MalaCards: mucopolidosis ii alpha/beta  
[http://www.malacards.org/card/mucopolidosis\\_ii\\_alpha\\_beta](http://www.malacards.org/card/mucopolidosis_ii_alpha_beta)
- Orphanet: Mucopolidosis type II  
[http://www.orpha.net/consor/cgi-bin/OC\\_Exp.php?Lng=EN&Expert=576](http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=576)

### Patient Support and Advocacy Resources

- ISMRD: The International Advocate for Glycoprotein Storage Diseases  
<http://www.ismrd.org/>
- Lysosomal Diseases New Zealand  
<http://www.ldnz.org.nz>
- National MPS Society  
<http://mpssociety.org/mps/ml-ii-ml-iii/>
- National Organization for Rare Disorders (NORD): I Cell Disease  
<https://rarediseases.org/rare-diseases/i-cell-disease/>
- The Canadian Society for Mucopolysaccharide & Related Diseases Inc.  
<http://www.mpssociety.ca>
- The MPS Society (UK)  
<http://www.mpssociety.org.uk/diseases/related-diseases/ml-ii/>

### GeneReviews

- Mucopolidosis II  
<https://www.ncbi.nlm.nih.gov/books/NBK1828>

### ClinicalTrials.gov

- ClinicalTrials.gov  
<https://clinicaltrials.gov/ct2/results?cond=%22mucopolidosis+type+II%22+OR+%22Mucopolidosis+Type+II%22>

## Scientific Articles on PubMed

- PubMed  
<https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28mucopolipidosis+type+ii%5BTIAB%5D%29+OR+%28i-cell+disease%5BTIAB%5D%29+OR+%28inclusion+cell+disease%5BTIAB%5D%29+OR+%28mucopolipidosis+ii%5BTIAB%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+3600+days%22%5Bdp%5D>

## OMIM

- MUCOLIPIDOSIS II ALPHA/BETA  
<http://omim.org/entry/252500>

## **Sources for This Summary**

- Bargal R, Zeigler M, Abu-Libdeh B, Zuri V, Mandel H, Ben Neriah Z, Stewart F, Elcioglu N, Hindi T, Le Merrer M, Bach G, Raas-Rothschild A. When Mucopolipidosis III meets Mucopolipidosis II: GNPTA gene mutations in 24 patients. *Mol Genet Metab*. 2006 Aug;88(4):359-63. Epub 2006 Apr 21. Erratum in: *Mol Genet Metab*. 2007 Jul;91(3):299.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/16630736>
- Braulke T, Pohl S, Storch S. Molecular analysis of the GlcNac-1-phosphotransferase. *J Inher Metab Dis*. 2008 Apr;31(2):253-7. doi: 10.1007/s10545-008-0862-5. Epub 2008 Apr 15. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/18425436>
- Cathey SS, Kudo M, Tiede S, Raas-Rothschild A, Braulke T, Beck M, Taylor HA, Canfield WM, Leroy JG, Neufeld EF, McKusick VA. Molecular order in mucopolipidosis II and III nomenclature. *Am J Med Genet A*. 2008 Feb 15;146A(4):512-3. doi: 10.1002/ajmg.a.32193.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/18203164>
- Cathey SS, Leroy JG, Wood T, Eaves K, Simensen RJ, Kudo M, Stevenson RE, Friez MJ. Phenotype and genotype in mucopolipidoses II and III alpha/beta: a study of 61 probands. *J Med Genet*. 2010 Jan;47(1):38-48. doi: 10.1136/jmg.2009.067736. Epub 2009 Jul 16.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/19617216>  
*Free article on PubMed Central:* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712854/>
- GeneReview: Mucopolipidosis II  
<https://www.ncbi.nlm.nih.gov/books/NBK1828>
- Kudo M, Brem MS, Canfield WM. Mucopolipidosis II (I-cell disease) and mucopolipidosis IIIA (classical pseudo-hurler polydystrophy) are caused by mutations in the GlcNac-phosphotransferase alpha / beta -subunits precursor gene. *Am J Hum Genet*. 2006 Mar;78(3):451-63. Epub 2006 Jan 24.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/16465621>  
*Free article on PubMed Central:* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1380288/>
- Otomo T, Higaki K, Nanba E, Ozono K, Sakai N. Lysosomal storage causes cellular dysfunction in mucopolipidosis II skin fibroblasts. *J Biol Chem*. 2011 Oct 7;286(40):35283-90. doi: 10.1074/jbc.M111.267930. Epub 2011 Aug 16.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/21846724>  
*Free article on PubMed Central:* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186395/>

- Otomo T, Muramatsu T, Yorifuji T, Okuyama T, Nakabayashi H, Fukao T, Ohura T, Yoshino M, Tanaka A, Okamoto N, Inui K, Ozono K, Sakai N. Mucopolipidosis II and III alpha/beta: mutation analysis of 40 Japanese patients showed genotype-phenotype correlation. *J Hum Genet.* 2009 Mar; 54(3):145-51. doi: 10.1038/jhg.2009.3. Epub 2009 Feb 6.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/19197337>
- Plante M, Claveau S, Lepage P, Lavoie EM, Brunet S, Roquis D, Morin C, Vézina H, Laprise C. Mucopolipidosis II: a single causal mutation in the N-acetylglucosamine-1-phosphotransferase gene (GNPTAB) in a French Canadian founder population. *Clin Genet.* 2008 Mar;73(3):236-44. doi: 10.1111/j.1399-0004.2007.00954.x. Epub 2008 Jan 7.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/18190596>
- Saul RA, Proud V, Taylor HA, Leroy JG, Spranger J. Prenatal mucopolipidosis type II (I-cell disease) can present as Pacman dysplasia. *Am J Med Genet A.* 2005 Jun 15;135(3):328-32.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/15887289>
- Takanashi J, Hayashi M, Yuasa S, Satoh H, Terada H. Hypomyelination in I-cell disease; MRI, MR spectroscopy and neuropathological correlation. *Brain Dev.* 2012 Oct;34(9):780-3. doi: 10.1016/j.braindev.2011.12.013. Epub 2012 Jan 24.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/22269149>
- Tiede S, Storch S, Lübke T, Henrissat B, Bargal R, Raas-Rothschild A, Bräulke T. Mucopolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase. *Nat Med.* 2005 Oct;11(10):1109-12. Epub 2005 Oct 2.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/16200072>
- Wilcox WR, Wenger DA, Lachman RS, Rimoin DL. Distinguishing Pacman dysplasia from mucopolipidosis II: comment on Saul et al. [2005]. *Am J Med Genet A.* 2005 Jun 15;135(3):333.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/15887286>

---

Reprinted from Genetics Home Reference:

<https://ghr.nlm.nih.gov/condition/mucopolipidosis-ii-alpha-beta>

Reviewed: May 2015

Published: March 21, 2017

Lister Hill National Center for Biomedical Communications  
U.S. National Library of Medicine  
National Institutes of Health  
Department of Health & Human Services